I'm a buyer today. Cantor's sell is right, right, right if your looking at this year's numbers only.
I have no doubt Adcetris will be approved frontline NHL and cd30 B-Cell. That is 10-20 times current approved indications. They now have just about a 2000 patient population which generates $140 ml. Do the math.
CD-30 cancer is larger than just NHL.
My peak Adceetris sales estimate is $1.5bil - $2bil. and a $100-$150 2016 share price.
While looking for stocks which can rise if the market turns down this fits the bill. No debt. No need to raise capital in an offering. Revenue growth which will go exponential.
SGEN is a no-brainer buy.
This is just my opinion. I'm long. Do your own research. This is not a recommendation to buy.
The Cantor opinion you reference was issued on Aug. 1, 2013. What you saw today was a roundup of previous - and in many cases old - recommendations by Cantor. From Seeking Alpha on Aug. 7, 2013: "On Thursday August 1st, Analysts at Cantor Fitzgerald issued a target price of $24 a share with a "sell" recommendation as they see the potential downside of the stock could drop 40.77% from its July 31st close."
Since that opinion by Cantor, the stock has advanced from $40.52 on July 31 to around $51, a gain of more than 25 percent.